GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Glucophage® | LA-6023
metformin is an approved drug (FDA (1995))
Compound class:
Synthetic organic
Comment: Metformin is the only FDA-approved biguanide class drug. It is formulated as metformin hydrochloride for clinical use. Metformin is often given in fixed-dose combinations with other antihyperglycemic agents.
Repurposing: Cancer cells undergo a metabolic switch to aerobic glycolysis, and become reliant on this metabolic pathway for energy (the Warburg effect). Inhibition of the glycolytic pathway is therefore considered as a tractable therapeutic target in oncology. As metformin is an inhibitor of glycolysis it is being examined for anti-cancer effects in a number of malignancies. Similarly, it is being examined for anti-inflammatory potential since activated immune cells also undergo a metabolic switch to aerobic glycolysis. If found to be effective, this could ultimately lead to metformin being repurposed for indications other than type 2 diabetes. View more information in the IUPHAR Pharmacology Education Project: metformin |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Although the underlying molecular mechanism is incompletely understood [1-2,4], evidence published in 2026 indicates that inhibition of mitochondrial complex I in the intestinal epithelium is crucial for metformin's therapeutic effect, rather than its effects in the liver as previously thought [8]. The biguanide phenformin and the natural product berberine also act through this mechanism. |
| Transporters Moving this Compound Across a Lipid Membrane | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||